The Food and Drug Administration approved the drug aducanumab to treat patients with Alzheimer's disease on Monday. It is the first new drug approved by the agency for Alzheimer's disease since 2003.

In this video, James E. Galvin, MD, MPH, professor of neurology and psychiatry and behavioral sciences at the University of Miami Miller School of Medicine, discusses how the treatment landscape for ...

This article is part of “Innovations In: Alzheimer's Disease” an editorially independent special report that was produced with financial support from Eisai. One of neurologist Anelyssa D’Abreu’s least ...

Researchers say a new experimental drug could be a game changer when it comes to treating Alzheimer's disease. Patients with early-stage Alzheimer's were given the drug aducanumab once a month for a ...

Eli Lilly and Company LLY announced that the European Commission (EC) has granted marketing authorization to Kisunla (donanemab) for the treatment of early symptomatic Alzheimer's disease (AD).